Stockscreener 앱 받기
0.82
3.24%
-0.0275
시간 외 거래:
.83
0.01
+1.22%
Humacyte Inc 주식(HUMA)의 최신 뉴스
Humacyte regains ex-US rights to Symvess from Fresenius Medical Care - MSN
H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $3 - Moomoo
Humacyte stock price target reiterated at $3 by H.C. Wainwright - Investing.com Canada
Barclays Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo
Humacyte Highlights Dialysis Access Data; Women Show Strong ATEV Edge, V012 Results Due in June - Yahoo Finance
Humacyte (HUMA) price target decreased by 31.82% to 5.46 - MSN
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $1 - Moomoo
Humacyte (NASDAQ: HUMA) 2026 proxy adds share increase vote - Stock Titan
Humacyte, Inc. (HUMA) stock sinks as market gains: Here's why - MSN
Humacyte Q4 2025 earnings preview - MSN
Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026 - The Manila Times
Humacyte webcast tackles dialysis access with Phase 3 results due - Stock Titan
Humacyte Expands Commercial and Business Development Opportunities through Realignment of Ex-U.S. Rights to Symvess - marketscreener.com
Humacyte (HUMA) takes ex-U.S. Symvess control as Fresenius retains 8.4% stake - Stock Titan
Humacyte Stock (HUMA) Opinions on Symvess Rights Realignment - Quiver Quantitative
Humacyte regains ex-U.S. rights to Symvess from Fresenius By Investing.com - Investing.com Australia
Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc.HUMA - PR Newswire
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Humacyte Is Maintained at Buy by D. Boral Capital - Moomoo
Humacyte gets global rights to Symvess from Fresenius (HUMA) - Seeking Alpha
FMS Partners with Humacyte to Restructure Symvess Distribution R - GuruFocus
Humacyte Realigns Ex-U.S. Rights to Symvess with Fresenius Medical Care to Accelerate International Commercial Expansion - Minichart
Humacyte Regains Global Rights to Symvess Vascular Graft - TipRanks
Humacyte Marketing Authorization for Symvess acellular vessel accepted by Israel Ministry of Health - Traders Union
Biotechnology company Humacyte, Inc. announces exclusive distribution rights for the innovative medical device Symvess outside the United States. - Bitget
Humacyte regains ex-U.S. rights to Symvess from Fresenius - Investing.com
Humacyte (Nasdaq: HUMA) regains ex-U.S. Symvess rights from Fresenius - Stock Titan
Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess® - The Manila Times
HUMA Should I Buy - Intellectia AI
Humacyte shares sink as it announces pricing of $60M direct offering - MSN
Humacyte shares plunge after announcing $60 million registered direct offering - MSN
Humacyte appoints Jim Mercadante as chief commercial officer By Investing.com - Investing.com Australia
HUMA (Humacyte Inc.) shares rise 3.8 percent after 2025 fourth quarter earnings narrowly top analyst expectations.Expert Verified Trades - Cổng thông tin điện tử tỉnh Tây Ninh
Humacyte appoints Jim Mercadante as chief commercial officer - Investing.com
Humacyte Appoints Jim Mercadante as Chief Commercial Officer - Yahoo Finance
1.39%
0.10%
자본화:
|
볼륨(24시간):